Jennifer Brown MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the novel agent acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL).
Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses clinical trials for potential treatments for patients with T-cell lymphoma.
Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of traditional agents in the treatment of patients with kidney cancer.
Michael J. Mauro, MD, a hematologist and leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center, discusses some of the emerging and current therapies for patients with myeloproliferative neoplasms (MPNs).
Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses how community oncologists can incorporate the NCCN Guideline for Myeloproliferative Neoplasms (MPNs) into clinical practice.
Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale School of Medicine, discusses the updates of a study of atezolizumab in patients with metastatic urothelial carcinoma (mUC).
Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses PD-1 expression in patients with chronic lymphocytic leukemia (CLL) who were treated with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica).
Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discuss the interest in studying venetoclax (Venclexta) in a phase II study for patients with chronic lymphocytic leukemia (CLL).
John M. Burke, MD, Rocky Mountain Cancer Centers, discusses the significant findings of the phase III GOYA study investigating obinutuzumab (Gazyva) plus CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses sequencing of new therapies for castration-resistant prostate cancer (CRPC).
W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses genetic conditions with predisposition for patients with kidney cancer.
Scott T. Tagawa, MD, Weill Cornell Medicine, discusses the updated results of a prospective biomarker anaylsis from the TAXYNERGY trial in patients with metastatic castration-resistant prostate cancer (mCRPC).
Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the potential of combinations between immunotherapy and conventional therapies in genitourinary cancers.
Fred Saad, MD, University of Montreal Hospital Centers, discusses the safety and efficacy of the apalutamide combination for patients with metastatic castration-resistant prostate cancer.
Jeffrey Jones, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University, discusses a concern of venetoclax (Venclexta) in a phase II study that evaluated the efficacy of venetoclax in the treatment of patients with chronic lymphocytic leukemia (CLL).
Michael J. Morris, MD, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with radium-223 treatment in prostate cancer.
David F. McDermott, MD, Beth Israel Deaconess Medical Center, discusses the recent IMmotion150 trial in Renal Cell Carcinoma (RCC).
William K. Oh, MD, professor, Mount Sinai Hospital, discusses the current role of chemotherapy in the treatment of patients with prostate cancer.
Julia White, MD, The Ohio State University Comprehensive Cancer Center, discusses brain metastases in patients with HER2-positive breast cancer.
Fred Saad, MD, professor and chief of Urology, Director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses radium-223 dichloride (Xofigo) for patients with prostate cancer.
Josh Armenia, PhD, Memorial Sloan Kettering Cancer Center, discusses the impact of a gene mutation analysis study in prostate cancer.
William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses a clinical trial exploring the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) in patients with chronic lymphocytic leukemia (CLL).
Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the efficacy reported with ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL).
Kevin Kalinsky, MD, assistant professor of Medicine at Columbia University Medical Center, discusses the potential advantages of optical imaging for patients with HER2-positive breast cancer.
Marcus Albertsmeier, MD, surgeon at Ludwig Maximilian University of Munich, discusses the effect of radiation therapy on local recurrence and overall survival for patients with soft tissue sarcoma.
Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses ongoing clinical trials in the field of head and neck cancer.
John Mascarenhas, MD, associate professor of Medicine, Mount Sinai School of Medicine, discusses pacritinib in patients with myelofibrosis.
Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the potential of immunotherapy in the treatment landscape of multiple myeloma.
Kevin R. Kelly, MD, PhD, associate professor of Medicine, Keck School of Medicine, discusses indatuximab ravtansine (BT062) in combination with lenalidomide (Revlimid) in patients with relapsed or refractory multiple myeloma.
Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses the combination of immunotherapy and radiation in patients with prostate cancer.
